A ABB is to be commended for engaging in its first exercise utilizing the risk-based decision-making (RBDM) framework. In 2016, AABB's Board of Directors tasked the Ad Hoc Babesia Policy Working Group to use the Alliance of Blood Operators (ABO) RBDM framework in assessing the risks and benefits of Babesia microti blood donation screening of the US blood supply. 1 Through this exercise, AABB and the broader blood community can work together to identify the strengths, weaknesses, and potential modifications to the RBDM framework to improve its utility for AABB and its membership. In this issue of TRANSFUSION, Ward and colleagues 1 present the recommendations of the Working Group (the "Babesia Report") based on the RBDM framework. The group's primary conclusion is that a regional approachscreening donors for Babesia in endemic states only-is appropriate as it targets the intervention to where the risk is highest and makes the best use of limited resources. The group endorses screening by nucleic acid testing (NAT) only and acknowledges the need to regularly reassess which states should be considered endemic. No changes to reimbursement mechanisms are recommended, but AABB is encouraged to monitor blood sector sustainability in endemic areas. Finally, AABB is asked to work with agencies such as the Centers for Disease Control and Prevention to educate the public about the health risks posed by Babesia. The full report of the Working Group can be accessed on the AABB Web site.
RBDM FRAMEWORK
AABB, the Food and Drug Administration (FDA), and blood collectors all work to promote a safe and adequate blood supply. As the standard-setting body for blood collection establishments, AABB has a unique role in helping to protect patient safety and is committed to advocating for policies that advance a safe and adequate blood supply. The FDA defines its role as "driv[ing] risk to the lowest level reasonably achievable without unduly decreasing the availability of this life saving resource." 2 Thus, it is recognized that risk tolerability is a key consideration for designing policies to safeguard the blood supply. The RBDM framework provides a tool that incorporates risk tolerability when assessing risk management options.
Developed by ABO, the RBDM framework represents a new paradigm in evaluating risks to blood safety. It is intended to provide decision makers with a "structured and systematic process" to consider factors related to blood safety, including emerging risks, evolving technology, societal and ethical issues, and economic factors and to help ensure that finite resources are allocated to the most significant risks (Fig. 1) . [3] [4] [5] ABO provided time and expertise and fully supported AABB in its use of the RBDM framework. 8 As more data become available and additional assays are FDA approved, the recommended testing algorithms will change. The sensitivity and specificity, species detected, and the logistics and costs of each of the assays greatly influence the outcome of the RBDM process and the FDA's own process, as both use a risk/cost-benefit model.
BABESIA RBDM REPORT

Babesia-endemic states
The Babesia Report, 1 taken in conjunction with the FDA Draft Guidance, 8 highlights the lack of consensus around which states should be treated as Babesia-endemic or as Babesia-risk states. 9 The known map of B. microti incidence is expanding. 10 
Need for data
The lack of clarity around states or areas of concern is exacerbated by the lack of reliable surveillance data, including tick and human (community-acquired, transfusion-transmitted, and donor testing) activity. Additionally, this would track TTB cases due to donor travel; 7% of TTB cases previously reported were either due to donor travel or a donor from an endemic area donating in a nonendemic area. 6 Babesiosis has been a nationally notifiable condition since 2011, yet in 2015, Babesia was only reportable in 33 states. Thus, every state is not currently mandated to report cases of Babesia and there is a delay between reporting and data publication. 12 Through its Biovigilance Network, AABB has a mechanism to track Babesia-positive blood donations geographically. Collaborating to improve reporting requirements and to understand risk tolerability will aid in determining policy.
Stakeholders
The RBDM framework calls for extensive and formal engagement of external stakeholders, including community and public health representatives as well as nonmedical individuals. The stakeholders for this exercise provided a clear reminder that the public tolerance for risk remains low. If public pressures drive zero-risk policies, policymakers will need to consider how to communicate risk tolerability and/or how to adequately and appropriately reimburse for public health initiatives in the context of the competitive market. Additionally, the stakeholder engagement that occurred during the Babesia RBDM process reinforced the need for education and public awareness related to tick-borne diseases, including babesiosis, apart from transfusion transmission. AABB should work with other public health agencies to help communicate the risks, signs and symptoms, prevention, and treatment of babesiosis, especially as 99% of the cases are tick-borne, although the morbidity and mortality is higher in transfusion-transmitted cases.
Economic disparities
Recognizing potential economic disparities that could result from a regional donor testing policy, the Babesia Report calls for performing a study to determine if these recommendations cause a "severe enough economic problem for blood operators in endemic states that it will be a threat to blood sector sustainability." Blood centers across the country are facing economic challenges such as increased costs associated with testing for West Nile Virus and Zika, continued decreases in use of red blood cell (RBC) transfusion, increased price competition, and other market variables. The addition of a regional versus national Babesia screening strategy will contribute to existing cost discrepancies. As a practical matter, blood centers may not be able to pass specific costs through to their customers, and some markets will not tolerate increased costs. The US blood system is fragile; a regional donor approach may result in some blood collectors having to leave the market before a retrospective analysis of the impact of the approach is complete, which may leave patients without a local blood supplier. Thus, there is a critical need for advocacy to lessen the financial impact.
Other considerations
Other factors not considered in the Babesia Report will need to be explored in the future. First, the report is unclear if testing is for all blood components or whether apheresis platelet (PLT) and plasma components are excluded. The FDA Draft Guidance excludes source plasma donations but includes all other blood donations. If risk tolerability is considered, apheresis PLT and plasma products should be excluded from testing as no definite case of TTB from these products has been reported. In the vast majority of cases, the implicated product is RBCs; approximately 5% of cases are linked to whole blood-derived PLTs. 13 Second, costeffectiveness studies vary due to underlying assumptions, such as TTB transmission probability, risk and severity of TTB, impact of TTB on quality of life, test performance, screening costs, and other costs such as data monitoring systems and legal costs of cases occurring in non-endemic regions. The Babesia Report uses one of multiple costeffectiveness Babesia screening studies without clearly stating the reasons for doing so. Third, donor reentry strategies are not addressed in the Babesia Report but are in the FDA Draft Guidance, which specifies a 2-year donor reentry period. This is important for blood centers that have ineligible donors due to testing performed under IND and will remain relevant as testing expands. Fourth, the Babesia Report does not consider the role of pathogen inactivation to replace donor testing despite data that show its potential for mitigating TTB. [14] [15] [16] These factors suggest the need for clear criteria for including and excluding relevant literature as well as the ability to integrate and apply new data in the RBDM process.
RBDM APPLIED TO THE UNITED STATES
The Babesia Report underscores potential challenges with using the ABO RBDM framework to evaluate policy options in the fragmented US blood community. Unlike the other countries where the RBDM framework is being used to inform decisions being made by national operators of blood services in the context of national health systems, the United States has a competitive blood system that exists as part of a competitive healthcare system comprised of hospitals, health systems, physicians, and insurance companies that compete in the same markets. Blood collection establishments make unique business decisions based on national, regional, local, and individual variables. Each blood center, hospital, health system, insurance company, and physician makes unique cost calculations and has different levels of risk tolerance. The AABB and blood operators should work together to assess how ABO's RBDM framework generally and this report specifically can incorporate the flexibility needed to enable each organization to meet patient safety and supply needs.
CONCLUSION
AABB should be congratulated for embracing RBDM and applying it to the complex topic of Babesia blood donor screening. The Babesia Report provides a new context in which to consider important challenges faced by the blood collection community, including the need to assess risk tolerability, public awareness, and mechanisms to reimburse donor centers for their additional costs to help keep the public safe. For Babesia testing strategy and policy, there remains inconsistency in defining endemic and nonendemic areas with expanding geography of babesiosis cases, evolving test development, and a lack of clarity about what constitutes acceptable risk. As the industry figures out how to move away from zero risk to risk tolerability, we need to find a process that is agile and able to incorporate new data and adjust for risk tolerability/cost-benefit analyses. It remains to be determined if the RBDM process can be modified to better suit the needs of AABB and its membership.
